GlassScriptPhysician profile
Darius J Marhamati
NPI 1811995897
$4,901.88
in general payments reported to CMS, 2019-2025
27 companies · $770 in 2025
The $770 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $284 · 2021: $607 · 2022: $885 · 2023: $598 · 2024: $657 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,024.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,161.37 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $740.62 | 2019-2025 | Jardiance |
| Amgen INC. | $583.87 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $507.11 | 2019-2023 | Xarelto |
| Pfizer INC. | $393.65 | 2019-2025 | |
| Scpharmaceuticals INC. | $157.46 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $156.89 | 2019-2024 | Farxiga, Wainua, Brilinta |
| Regeneron Healthcare Solutions, INC. | $149.97 | 2019-2024 | Evkeeza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $132.71 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $132.03 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $117.61 | 2021-2024 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $96.28 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $94.17 | 2019-2022 | |
| Tactile Systems Technology INC | $68.83 | 2025 | Flexitouch Plus, Nimbl |
| Bayer Healthcare Pharmaceuticals INC. | $65.75 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $64.11 | 2024 | Arcalyst |
| Chiesi USA, INC. | $54.37 | 2019-2020 | |
| Amarin Pharma, INC. | $43.11 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $34.27 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $32.36 | 2024 | Injectafer |
| Alnylam Pharmaceuticals INC. | $21.14 | 2025 | Onpattro |
| Astellas Pharma US INC | $19.76 | 2019 | |
| Esperion Therapeutics, INC. | $18.28 | 2024 | Nexletol |
| Abiomed | $15.50 | 2024 | Impella |
| Mannkind Corporation | $15.32 | 2025 | |
| Novo Nordisk INC | $12.95 | 2022 | |
| Medtronic, INC. | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darius Marhamati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.